AbbVie plans major shift of workers to Mettawa

    In what could eventually be one of the largest shifts of employees in the Chicago area in years, AbbVie Inc. is planning to fill a 558,859-square-foot office property in north suburban Mettawa over the next few years.

    The North Chicago-based pharmaceutical firm, a spinoff of Abbott Laboratories, today told employees about the move to space at interconnected 13-story towers at 26525 N. Riverwood Blvd. The move will be staged over the next few years, according to someone familiar with the plan.

    AbbVie will shift as many as 2,000 employees about seven miles south to Mettawa, according to the Chicago Tribune, which first reported the move. The first 250 to 500 workers, from teams that work to get new treatments approved by regulators and then sold, will start moving by the end of June, AbbVie told the Tribune.

    Read more in Crain’s Chicago Business.

    In what could eventually be one of the largest shifts of employees in the Chicago area in years, AbbVie Inc. is planning to fill a 558,859-square-foot office property in north suburban Mettawa over the next few years.


    The North Chicago-based pharmaceutical firm, a spinoff of Abbott Laboratories, today told employees about the move to space at interconnected 13-story towers at 26525 N. Riverwood Blvd. The move will be staged over the next few years, according to someone familiar with the plan.

    AbbVie will shift as many as 2,000 employees about seven miles south to Mettawa, according to the Chicago Tribune, which first reported the move. The first 250 to 500 workers, from teams that work to get new treatments approved by regulators and then sold, will start moving by the end of June, AbbVie told the Tribune.

    Read more in Crain's Chicago Business.

    BIZEXPO | EARLY BIRD PRICING | REGISTER BY MAY 10TH AND SAVE

    Stay up-to-date with our free email newsletter

    Keep up with the issues, companies and people that matter most to business in the Milwaukee metro area.

    By subscribing you agree to our privacy policy.

    No, thank you.
    Exit mobile version